Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Running

iAds Intelligent design of adenovirus vectors (iAds)

Coordinator
Centre National De La Recherche Scientifique CNRS, France
Runs
1 May 2023 to 30 April 2027
Status
Running
EU funding
€4.0m
Total cost
€4.0m
Partners
9 organisations in 6 countries
Type
European Innovation Council
Grant agreement
101098647

What the project is doing

In the project's own words, from its summary on CORDIS.

Advanced therapies, and in particular gene therapies, hold great potential for treating diseases for which few options exist. Efficient gene transfer is inherently and intransigently linked to vector efficacy. Partially due to the lack of suitable delivery systems for particular applications, the success of too many gene therapies is limited. Over the last two decades, immense progress has been made in the development of viral vectors.

Importantly, this progress has also identified vector characteristics and biological factors that decrease efficacy. While limited efficacy is relevant for all vector platforms, it is more pressing in the case of adenoviruses because they have so much potential. In some cases, host responses and imperfect targeting have stunted adenovirus vector development for therapies that require long-term transgene expression. Our multi-faceted consortium proposes an innovative approach to overcome these limitations and to construct a pathway for developing improved vectors for clinical gene transfer.

By synergising French, Dutch, British, Spanish and Swedish expertise in structural biology, receptor engagement, neurobiology, cardiobiology, and bioprocessing, we will create in silico designed intelligent adenovirus vectors (iAds). Our disruptive concept abandons the classical approach of developing vectors from naturally occurring adenoviruses. Instead, a proprietorial adenovirus type will be serially stripped of unwanted elements to create a bank of iAds, which will then be engineered for heart- and brain-specific targeting.

Our consortium blends academic ingenuity and SME/pharma manufacturing that will allow seamless clinical translation. With the support of the EIC Programme, our ground-breaking approach should revolutionise gene transfer and generate solutions in areas of unmet medical need via a platform that exploits the full potential of viral vectors.

Topics

Who is involved

OrganisationCityCountryRole
Centre National De La Recherche Scientifique CNRSParisFranceCoordinator
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceThird party
Universite De MontpellierMontpellierFranceThird party
Vilniaus UniversitetasVilniusLithuaniaParticipant
Batavia Biosciences BVLeidenNetherlandsParticipant
Janssen Vaccines & Prevention BVLeidenNetherlandsParticipant
Umea UniversitetUmeaSwedenParticipant
The University of EdinburghEdinburghUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI